­Nevro to Report Second Quarter 2020 Financial Results

Rhea-AI Summary

Nevro Corp. (NYSE: NVRO) plans to release its financial results for Q2 2020 on August 5, 2020, after market close. A conference call will follow at 1:30 pm PT to discuss these results. Investors can access the call by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally, using Conference ID: 8783575. Nevro is a global medical device company specializing in innovative solutions for chronic pain management, notably through its proprietary HF10 therapy, which has shown a significant ability to reduce opioid usage.

REDWOOD CITY, Calif., July 20, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 after the market closes on August 5, 2020.

Management will host a conference call on August 5, 2020 to discuss second quarter 2020 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally, using Conference ID: 8783575. In addition, a live webcast, as well as an archived recording, will be available on the "Investors" section of the Company's website at: www.nevro.com.

About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza^® System, Senza II™ System, and the Senza^® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10^® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investor Relations:
Juliet Cunningham
Vice President, Investor Relations
650-433-3247
ir@nevro.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-report-second-quarter-2020-financial-results-301095876.html

SOURCE Nevro Corp.

FAQ

When will Nevro Corp. report its Q2 2020 financial results?

Nevro Corp. will report its Q2 2020 financial results on August 5, 2020, after market close.

What is the conference call schedule for Nevro's Q2 2020 results?

The conference call will take place on August 5, 2020, at 1:30 pm PT.

How can I access Nevro's conference call?

Investors can access the call by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally, using Conference ID: 8783575.

What is HF10 therapy developed by Nevro?

HF10 therapy is a non-pharmacologic neuromodulation platform that has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies.

What products does Nevro offer for chronic pain treatment?

Nevro offers the Senza spinal cord stimulation systems, which include the Senza, Senza II, and Senza Omnia systems that deliver HF10 therapy.